Unlock instant, AI-driven research and patent intelligence for your innovation.

High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof

A PD-L1, antibody technology, applied in the direction of antibody, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, anti-tumor drugs, etc., can solve the problem of reaching the effective level of chemotherapeutic agents, but the results are not satisfactory People's Choice, etc.

Pending Publication Date: 2020-11-17
ABEOME CORP
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Currently available therapeutic strategies for the treatment of solid tumors result in large part from the difficulty in achieving therapeutically effective levels of chemotherapeutic agents in areas of tumor growth and infiltration
Usually, treatment is based on surgery and / or radiation therapy and / or chemotherapy, but these methods produce unsatisfactory results in a significant percentage of cases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
  • High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
  • High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0148] Transgenic mice overexpressing mouse Ig-α, mouse Ig-β, and human interleukin-6 were injected intraperitoneally with recombinant human PD-L1 (R&D Systems) at 2-week intervals. After establishing a significant immune response as measured by serum ELISA, lymph node, spleen, and bone marrow cells were harvested, B cells expressing IgM isotype antibodies on the surface were subtracted using magnetic beads, and the remaining cells were targeted using a MoFlo fluorescence-activated cell sorter. Cells were sorted for their ability to bind PD-L1.

[0149] Cells positive for PD-L1 binding were sorted into 96-well plates, single-cell RT-PCR was performed to amplify the variable region, and the variable region was cloned into a heavy chain human IgG1 or IgG4 constant region or light chain In the expression vector of human Igk constant region. The resulting heavy and light chain clonal pairs were transfected into CHO cells, and the resulting antibody proteins were purified using pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are novel PD-L1 binding molecules and methods of their use. The disclosed PD-L1 binding molecules include neutralizing anti-PD-L1 antibodies, bi-specific antibodies, and immunotoxins.The description provides for the use of the disclosed PD-L1 binding molecules in the treatment, prevention, inhibition, or reduction of a cancer or metastasis or as part of a treatment regimen including the use of other anti-cancer agents.

Description

[0001] This application claims the benefit of U.S. Provisional Application No. 62 / 644,832, filed March 19, 2018, which is incorporated herein by reference in its entirety. Background technique [0002] Currently available therapeutic strategies for the treatment of solid tumors result in large part from the difficulty in achieving therapeutically effective levels of chemotherapeutic agents in areas of tumor growth and infiltration. Usually, treatment is based on surgery and / or radiotherapy and / or chemotherapy, but these methods produce unsatisfactory results in a significant percentage of cases. Thus, there is a clear need to improve currently available therapies for the treatment of cancers involving solid tumors, and / or to develop new therapies targeting such solid tumors. Contents of the invention [0003] In one aspect, disclosed herein are binding molecules directed against PD-L1 that are useful in the treatment of PD-L1 mediated diseases and disorders. [0004] In one...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28G01N33/577
CPCC07K16/2827C07K2317/24C07K2317/76C07K2317/92A61P35/00C07K2317/565A61K2039/505
Inventor R·施姆克斯T·文森特C·杰克逊
Owner ABEOME CORP